Vaxart Announces Its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study

Published: 1/02/2018
Vaxart Announces Its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study
Source: WWW.BUSINESSWIRE.COM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that its investigational H1 influenza oral tablet vaccine demonstrated a statistically significant reduction in the rate of influenza infection compared with placebo, and compared favorably

Read more
Related news
Comment